160
Participants
Start Date
June 30, 2006
Primary Completion Date
January 31, 2008
Study Completion Date
April 30, 2012
Everolimus 10 mg
Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
Octreotide Depot
Lynn Ratner, M.D., New York
Novartis Investigative Site, Milan
Duke University Medical Center, Durham
Novartis Investigative Site, Madrid
Emory University Hospital, Atlanta
University of Miami, Miami
H. Lee Moffit Cancer Center & Research Institute, Tampa
The University of Alabama at Birmingham, Birmingham
Arthur G. James Cancer Hospital/Ohio State University, Columbus
University of Iowa Hospitals and Clinics, Iowa City
University of Wisconsin Hospital & Clinics, Madison
Mayo Clinic, Rochester
Novartis Investigative Site, Pisa
Novartis Investigative Site, Torrette Di Ancona
LSUHC Multispecialty Clinic, New Orleans
Scott & White Memorial Hospital, Temple
M. D Anderson Cancer Center, Houston
USC Medical Center, Los Angeles
Cedars-Sinai Outpatient Cancer Center/Samuel Oschin Comprehensive Cancer Inst., Los Angeles
UCLA Medical Center, Los Angeles
Novartis Investigative Site, Billancourt
Novartis Investigative Site, Clichy
UCSF Comprehensive Cancer Center, San Francisco
Dana Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
Oregon Health and Science University, Portland
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Santa Fe
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Herston
Novartis Investigative Site, Kogarah
Novartis Investigative Site, Leuven
Novartis Investigative Site, Reims
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Berlin
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Essen
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Marburg
Novartis Investigative Site, Ulm
Novartis Investigative Site, Modena
Novartis Investigative Site, Gronigen
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Uppsala
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Halifax
Novartis Investigative Site, London
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Lyon
Novartis Investigative Site, Rome
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY